🟢 Icecure Medical is trading 13.64% up in pre-market after first ChoICE study site approved

Icecure Medical is trading 13.64% up at $3.50 after Adventist Health Glendale became the first approved site to enroll patients in the post-marketing ChoICE study for ProSense breast-cancer treatment.

• The August 6 announcement provides a clear company-specific catalyst, while broader healthcare strength may be adding support.
• The company is scheduled to report first-half 2026 financial and operating results before market open on August 12.